Six brokerages set USD 1.71 target for Pacific Biosciences stock

Published on 10/15/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PacBio reports third-quarter results on November 4, 2026. Pacific Biosciences stock costs EUR 1.76 on October 15, 2026 at 9:11 p.m. CEST.

Analyst view and trading levels

Six brokerages assigned a consensus target of USD 1.71 on October 10, 2026.
PacBio will discuss third-quarter 2026 results on November 4, 2026.
Pacific Biosciences stock costs EUR 1.76 at Lang & Schwarz on October 15, 2026 at 9:11 p.m. CEST.
The company had a market capitalization of USD 615.4 million and a negative P/E ratio of 4.59 as of October 15, 2026.

PACB, US69404D1081, Illustration mit AI erstellt.

Pacific Biosciences (ISIN US69404D1081) has a consensus 12-month price target of USD 1.71 from six brokerages, while the average rating is Reduce, according to MarketBeat on October 10, 2026. The target is 13.64 percent below the USD 1.98 Nasdaq price at the latest October 15, 2026 quote. Pacific Biosciences stock was trading at EUR 1.76 at Lang & Schwarz on October 15, 2026 at 9:11 p.m. CEST.

The target stays below the quote

The analyst picture is cautious rather than uniform. MarketBeat reported two Sell ratings, three Hold ratings and one Buy rating among the six brokerages, alongside the USD 1.71 average target. UBS had initiated coverage with a Neutral rating and a USD 1.35 target on September 9, 2026, according to the same report.

That target sits below the latest Nasdaq quote, but the comparison uses different analyst views rather than a company forecast. The spread between the consensus target and the market price gives the analyst view a concrete counterweight to the recent trading range.

Trading range remains wide

On Nasdaq, PACB was last at USD 1.98 on October 15, 2026 at 3:16 p.m. EDT. The finance quote showed a session range of USD 1.86 to USD 1.98, volume of 10,154,414 shares against an average of 10,823,054, and a 52-week range of USD 1.07 to USD 3.44.

At USD 1.98, the stock stood 42.44 percent below its 52-week high and 85.05 percent above its 52-week low. The company had a market capitalization of USD 615.4 million and a negative P/E ratio of 4.59 as of October 15, 2026.

November results set the next date

PacBio announced on October 14, 2026 that it will discuss third-quarter 2026 financial results on November 4, 2026, at 4:30 p.m. ET. The scheduled call is the next dated corporate event in the company calendar. The latest completed quarterly figures cited by MarketBeat were revenue of USD 39.01 million and an adjusted? no, reported quarterly loss of USD 0.14 per share, versus consensus revenue of USD 42.90 million and consensus loss of USD 0.13 per share.

Market comparison

PACB (Nasdaq, USD): daily change not stated, P/E minus 4.59, market capitalization USD 615.4 million.

Illumina (Nasdaq, USD): plus 0.95 percent, P/E 51.13, market capitalization USD 41.4 billion.

10x Genomics (Nasdaq, USD): minus 1.05 percent, P/E minus 122.58, market capitalization USD 9.4 billion.

European trading view

The euro quote provides the German trading perspective, while the Nasdaq quotation supplies the company-specific range and valuation figures. The next scheduled results date gives investors a defined calendar marker for the next fundamental update.

Pacific Biosciences stock was trading at EUR 1.76 at Lang & Schwarz on October 15, 2026 at 9:11 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Pacific Biosciences stock.